To investigate whether cigarette smoking and/ or depression contribute to neonatal abstinence syndrome (NAS) severity.
Measurements:
Smoking data and depression status were obtained from the Addiction Severity Index and Mini International Neuropsychiatric Interview, respectively. Neonatal outcomes (birth weight, preterm delivery, and NAS pharmacologic treatment) were collected from the medical charts. Study site was a fixed-effect factor in all analyses.
Findings:
Cigarette smoking was reported by 94% of participants and depression identified in 35%. Smoking was associated with low birth weight, preterm delivery, and NAS pharmacologic treatment in both depressed and nondepressed participants. The association between smoking and NAS treatment differed significantly between depressed and nondepressed participants. Among nondepressed participants, adjusting for site and illicit drug use, each additional average cigarette per day (CPD) increased the odds of NAS treatment by 12% (95% confidence interval: 1.02-1.23; P = 0.02). Among depressed participants, each additional average CPD did not statistically increase the odds of NAS treatment (odds ratio: 0.94; 95% confidence interval: 0.84-1.04; P = 0.23).
Conclusions:
These results are consistent with the hypothesis that NAS expression is influenced by many factors. The relationship between CPD and NAS pharmacologic treatment is attenuated among depressed women in this study for reasons currently unknown. Further investigations are needed to clarify the complex relationships among maternal smoking, depression, and NAS.
Key Words: cigarettes, depression, neonatal, pregnancy, opioids (Addict Disord Their Treatment 2011;10:180-187) I n an effort to improve the maternal and infant health outcomes of opioid-dependent pregnant women, stabilization on therapeutic doses of methadone in the context of prenatal care and ancillary services has been the accepted standard of care. 1 More recently, buprenorphine has been evaluated in randomized clinical trials for the treatment of opioid dependence during pregnancy. [2] [3] [4] Prenatal exposure to methadone and other opioids including buprenorphine, often leads to neonatal abstinence syndrome (NAS) in the newborn. NAS in prenatally opioid-exposed newborns is a constellation of signs and symptoms representing central nervous, autonomic, respiratory, and gastrointestinal dysregulation 5 such as hypertonicity, tachypnea, feeding problems, and irritability. 6 Although almost all opioid-exposed infants express some signs of NAS, the presentation varies widely and only a subset of these infants develop signs severe enough to require pharmacologic treatment. 7 suggest that the severity of NAS expression is unrelated to maternal methadone dose. [7] [8] [9] [10] [11] Numerous other factors, such as placenta efflux transporters, antidepressant medication exposure, and infant vagal tone, may modulate NAS expression existence and require further study. 4, [12] [13] [14] [15] [16] [17] [18] [19] Maternal cigarette smoking is one of the many variables postulated to affect NAS expression. There have been several reports that indicate an association between heavy maternal nicotine exposure and severity of NAS expression. 4, [14] [15] [16] [17] [18] However, because at least 90% of opioid-dependent pregnant patients smoke cigarettes, 14, 16, 18, [20] [21] [22] [23] it has been challenging to disentangle this variable from the other potential risk factors for NAS severity.
Another variable frequently found in opioid-dependent pregnant smokers, 24 which may also play a role in NAS expression, is maternal depression. Up to 50% of opioid-dependent pregnant women who smoke are also depressed, 25 and depression is causally linked to numerous other adverse neonatal outcomes. 26, 27 However, the contribution of maternal depression in opioid-dependent women to NAS expression has not been previously examined, nor have studies of maternal cigarette smoking and NAS concurrently examined the impact of the presence of co-occurring maternal depression on NAS.
In this study we aim to expand on the previous literature by examining whether maternal cigarette smoking and/ or depression contribute significantly to the severity of NAS expression in the infant. This study will explore the possibility that maternal cigarette smoking and depression may have additive or synergistic effects on NAS severity in the infant.
METHODS

Sites
This is a secondary analysis of data from the multisite MOTHER study, which examined the comparative safety and efficacy of methadone and buprenorphine in the treatment of opioiddependence among pregnant women and their neonates. 28 Participants Participants in this cohort study were selected from 131 opioid-dependent agonist-maintained pregnant patients who completed a multisite randomized controlled, double blind, double-dummy intervention trial of methadone versus buprenorphine.
Eligibility and Categorization of Participants Into Groups
Of the 131 participants who took part in the randomized controlled trial, 12 were excluded due to missing data on key variables: 7 lacked information on cigarette smoking, 3 lacked maternal urine toxicology screens within 2 weeks of delivery, and 2 lacked data on infant NAS treatment. A total of 119 women had complete data for the outcomes and covariates of interest and therefore were eligible for inclusion in the subsequent cohort analyses. Both smokers (n = 112) and nonsmokers (n = 7) were included in the study cohort. Smoking status was identified based on self-report, and their cigarette smoking quantified using the Addiction Severity Index (ASI) [29] [30] [31] at study entry and during study period. Both depressed participants (n = 42) and nondepressed (n = 77) participants were included in the study cohort. Depression status was identified based on Mini International Neuropsychiatric Interview (MINI) 32 screening at study entry.
Measures
ASI
All participants completed a modified ASI 5.0, 30 a semistructured interview assessing lifetime (study entry only) and past month pretreatment psychosocial functioning (study entry and monthly follow-up before delivery). For this study, number of cigarettes per day (CPD) smoked by the participant over study period was averaged and comparisons were made between average CPD and neonatal outcomes.
MINI
All participants at study entry completed the MINI, a brief structured diagnostic psychiatric interview designed for multicenter clinical trials and epidemiology studies. 32 Endorsement of 1 or both of 2 items (''Have you been consistently depressed or down, most of the day, nearly every day, for the past 2 weeks?''; ''In the past 2 weeks, have you been less interested in most things or less able to enjoy the things you used to enjoy most of the time?'') has been demonstrated to be a reliable and valid indicator of the presence of a current episode of major depressive disorder. 32 For this study, patients were categorized as depressed or nondepressed based on the response to these 2 items on the MINI.
Neonatal Medical Documentation
Neonatal outcomes were collected from the medical charts and included birth weight, preterm delivery (< 37 wk) (yes vs. no), and administration of NAS pharmacologic treatment (yes vs. no).
Analyses
Baseline demographics and rates of maternal cigarette smoking, substance use, and antidepressant treatment were tabulated. Rates of adverse neonatal outcomes (low birth rate, preterm delivery, and NAS pharmacologic treatment) were tabulated for the total sample, and separately, for depressed and nondepressed mothers. Univariate and bivariate logistic regression was used to assess potential risk factors (and their interactions) for NAS pharmacologic treatment. Linear combinations of parameter estimates were used to calculate the point estimates and confidence intervals (CI) for the increase in odds of NAS treatment associated with each additional cigarette, separately for depressed and nondepressed individuals. Site was a fixedeffect factor in all analyses: urban US (Baltimore, MD; Philadelphia, PA; Detroit, MI; Providence, RI) versus rural US (Burlington, VT; Nashville, TN) versus urban European (Vienna), the latter of which was the control site for the parametric analyses. Pooling the sites minimized the possibility that site heterogeneity might adversely impact the analyses. Maternal illicit drug use is a well-known risk factor for adverse neonatal outcomes and therefore adjusting for maternal urine toxicology screens positive for illicit drugs minimized the possibility that this factor might adversely impact the analyses. All analyses were performed with the randomized controlled intervention trial blind intact.
RESULTS
Participant Characteristics: Study Entry
Maternal demographic, substance use, cigarette smoking, and depression data at study entry are shown in Table 1 . All participants were opioid-dependent, but 29% and 13% at study entry were also using cocaine and marijuana, respectively. Over 90% reported smoking cigarettes and 35% of women were screened positive for major depressive disorder. 
ADDICTIVE
DISORDERS & THEIR TREATMENT
Participant Characteristics: During Treatment
Cigarette smoking, depression, antidepressant medication, and illicit drug use during study period are shown in Table 2 . Most (94%) of the participants reported smoking cigarettes, with an average number of CPD of 11.3 (SD = 6.5). Twenty-nine percent of participants used antidepressant medication. At least once during the study period, 25% of participants tested positive for illicit opioids, 17% for cocaine, 14% for cannabis, and 8% for sedatives. However, only 9% tested positive for any illicit drug within 2 weeks of delivery.
Total Sample Neonatal Outcomes: Low Birth Weight and Preterm Delivery
Maternal cigarette smoking, adjusting for site, and illicit drug use, was associated with lower birth weight (b: -20.49; 95% CI: -35.42, -5.55; P < 0.01) but not with lower gestational age at delivery (b: -0.03; 95% CI: -0.09,0.03; P = 0.33) among both depressed and nondepressed patients. The association between maternal smoking and low birth weight was attenuated, but still persisted after adjusting for estimated gestational age (b: -15.44; 95% CI: -26.54, -4.35; P < 0.01). 
Total Sample Neonatal Outcomes: Administration of NAS Pharmacologic Treatment
Neonatal Outcomes by Maternal Depression and Smoking Status
Neonatal outcomes by maternal depression status are shown in Table 3 . About half of the total sample's offspring were administered NAS pharmacologic treatment. Table 4 shows results of the univariate analyses, which show that infants born to depressed women were significantly less likely to need NAS treatment. Although CPD was not associated with NAS treatment in the univariate analyses, because this variable has been implicated in NAS development and severity in past studies 4,14-18 it was included in the multivariate analyses, which are shown in Table 5 . These analyses and the linear combinations in Table 6 , reveal that the association between smoking and administration of NAS pharmacologic treatment differed between depressed and nondepressed patients. Among nondepressed mothers, adjusting for site and illicit drug use, each additional average CPD increased the odds of administration of NAS pharmacologic treatment by 12% (95% CI:1.02,1.23; P = 0.02). The OR for the association between maternal depression and NAS pharmacologic treatment, adjusting for average CPD, site and illicit drug use, was 3.81 (95% CI: 0.66-21.92; P = 0.13). There was a statistically significant interaction between maternal depression and average CPD (ratio of ORs: 0.84; 95% CI: 0.72,0.97; P = 0.02), such that among depressed mothers, adjusting for site and illicit drug use, each additional average CPD did not statistically increase the odds of NAS pharmacologic treatment (OR: 0.94; 95% CI: 0.84-1.04; P = 0.23). Additional analyses revealed no significant association between selective serotonin reuptake inhibitor antidepressant treatment and NAS pharmacologic treatment, adjusting for CPD, illicit drug use, depression, and cigarette smoking/ depression interaction (OR: 1.66; 95% CI: 0.64,4.29; P = 0.30).
No significant association between maternal illicit drug use within 2 weeks of delivery and NAS pharmacologic treatment, adjusting for CPD, depression, and cigarette smoking/depression interaction, was found (OR: 0.63; 95% CI: 0.14, 2.79; P = 0.54).
DISCUSSION
The finding that the average number of CPD smoked by a nondepressed opioid-agonist-maintained pregnant woman is a factor that predicts her offspring's subsequent need for NAS pharmacologic treatment is not surprising. Although the finding that the same relationship is not true for the offspring of depressed women was unexpected, both are compatible with the wellrecognized association of smoking with poor neonatal outcome 33 and the hypothesis that NAS expression is influenced by multiple factors. 13, 17, 19 Alterations in maternal 34 and infant 13 autonomic functioning have been found to be associated with NAS severity in opioidexposed pregnancies, and the role of fetal programming has been implicated in underlying deficits present in alcohol-exposed children. 35, 36 Epigenetic alterations and fetal programming have also been implicated in NAS expression. 37, 38 Further studies regarding the relationship between adult autonomic function and depression in both children and adults [39] [40] [41] [42] suggest that depressed psychiatric patients have elevated levels of plasma catecholamines and other markers of altered autonomic function compared with nondepressed controls. The relationship between CPD and NAS pharmacologic treatment is attenuated among depressed women in this cohort of mother-infant dyads for reasons currently unknown. However, the suggestion that maternal depression results in altered maternal autonomic functioning and, through fetal programming, may affect the infant's autonomic functioning, which may be expressed exutero as more severe NAS expression, warrants further study. Possible mechanisms for the attenuated relationship between smoking and NAS among depressed women in this study may include maternal smoking being a stronger determinant of adverse neonatal outcomes compared with maternal depression. Thus, maternal smoking may eclipse the effect of depression on NAS expression and antidepressant medication treatment, which may mitigate the effect of maternal smoking on NAS expression in infants born to opioiddependent depressed mothers. These findings are provocative and clearly highlight the need for further research regarding the interaction of cigarette smoking, depression, and NAS in opioid-dependent pregnant patients.
There are several limitations of this study. First, data were collected as part of a larger randomized controlled trial. As a result, this study was not optimally designed to examine the variables of maternal cigarette smoking and depression. Although, it used a broadly defined self-report measure of both smoking and depression, a prospective trial on this topic could include more comprehensive and sensitive measures (eg, biological measurement of smoking through carbon monoxide and/ or cotinine; diagnosis of depression through clinical examination and/or lengthier structured clinical interview). The sample sizes of the examined groups are small and variable, which may limit the power and ability to detect all differences of interest. Ongoing measures of depression in the participants were not conducted limiting the interpretation of the role of antidepressant medication treatment in these women. Addressing these limitations would yield results supporting stronger conclusions. However, this study represents a first step in understanding the possible interaction between maternal cigarette smoking and depression in the expression of NAS.
This study provides some of the first data examining the complex relationship among concomitant prenatal exposure to opioid-agonist medication, cigarette smoke, and maternal depression on NAS. Although the health risks of maternal opioid medication treatment, cigarette smoking, and depression during pregnancy are independently well known for both mother and neonate, as a constellation these factors have received less attention. This study is a first attempt at exploring some of these complex relationships. In addition, this study measured CPD as a continuous variable, in contrast with previous studies of maternal cigarette smoking and NAS, which measured CPD as a dichotomous variable. Measurement of CPD as a continuous variable may improve the ability to detect maternal smoking effects on NAS expression.
Thus, future research must focus on several important issues. First, examining whether the type of opioidagonist medication (ie, methadone vs. buprenorphine) to which the fetus is exposed alters the interaction among cigarette smoking, depression, and NAS is indicated given the previous differential findings between methadone and buprenorphine regarding the relationship between smoking and NAS. 18 Second, characterizing how other combinations of the specific risk factors (ie, type of opioid-agonist medication, presence or absence of cigarette smoking, cigarette smoking profiles, and/or depression during various stages of pregnancy) exacerbate or mitigate negative maternal and neonatal outcomes is needed. Third, how opioid-dependence, which is the focus of treatment, in combination with cigarette smoking and depression, fuels negative biobehavioral outcomes in these women and their offspring is of interest. Fourth, identifying and implementing safe and effective treatments to reduce and eliminate smoking over the course of pregnancy to improve maternal and child health is imperative, especially in opioid-dependent patients who are at great risk for compromised maternal and neonatal outcomes.
